Quality of life effect of Lutathera in NETTER-1 trial for neuroendocrine tumors is published in Journal of Clinical Oncology.- Novartis + Advanced Accelerator Applications.
Novartis announced that the Journal of Clinical Oncology has published results of an analysis of the impact of Lutathera (lutetium Lu 177 dotatate) treatment on time to deterioration in HRQoL(health-related quality of life) in the pivotal phase III NETTER-1 trial. The data demonstrate that treatment with Lutathera provides significantly longer time to deterioration of quality of life for patients with progressive midgut Neuroendocrine tumors (NETs) compared to octreotide LAR alone.
Lutathera is the first Peptide Receptor Radionuclide Therapy (PRRT) to receive regulatory registration, with approval by the European Commission in September 2017 and by the FDA in January 2018. Lutathera is an Advanced Accelerator Applications product.
TTD (time to deterioration) was significantly longer in the Lutathera arm versus the comparator arm for the following domains: global health status (self-assessment of overall health and quality of life), physical functioning, role functioning, fatigue, pain, diarrhea, disease related worries and body image. Differences in median TTD were clinically significant in several domains: 28.8 months vs. 6.1 months for global health status, and 25.2 months vs. 11.5 months for physical functioning. Domains where Lutathera treatment did not show a significant benefit in TTD include nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, financial difficulties, endocrine scale (flushing, sweats), GI scale (bloating, flatulence), treatment scale, social functioning scale, muscle/bone pain, sexual function, and information/communication function. There were no domains in which TTD analysis showed significant benefit for the comparator arm.
See-
Strosberg J, Wolin E, Chasen B, et al. "Health related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 Trial". JCO 2018.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins